Quick Answer
Moleculin Biotech, Inc. reported Operating Income Loss of -$25.10 million for the year ending 2025.
- Moleculin Biotech, Inc. showed an increase of +5.8% in Operating Income Loss from 2024 to 2025.
- This data is from Moleculin Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: -$222.8 thousand | Q1 2016: -$321.0 thousand | Q2 2016: -$724.0 thousand | Q3 2016: -$1.42 million | Q1 2017: -$1.54 million | Q2 2017: -$1.32 million | Q3 2017: -$2.40 million | Q1 2018: -$2.64 million | Q2 2018: -$5.46 million | Q3 2018: -$2.59 million | Q1 2019: -$4.57 million | Q2 2019: -$3.63 million | Q3 2019: -$4.51 million | Q1 2020: -$5.06 million | Q2 2020: -$5.03 million | Q3 2020: -$6.15 million | Q1 2021: -$6.09 million | Q2 2021: -$5.52 million | Q3 2021: -$6.16 million | Q1 2022: -$7.07 million | Q2 2022: -$7.43 million | Q3 2022: -$9.08 million | Q1 2023: -$8.35 million | Q2 2023: -$6.41 million | Q3 2023: -$5.95 million | Q1 2024: -$6.68 million | Q2 2024: -$6.19 million | Q3 2024: -$7.14 million | Q1 2025: -$5.94 million | Q2 2025: -$5.72 million | Q3 2025: -$5.91 million.
- Over the full 10 years of available data (2016 to 2025), Moleculin Biotech, Inc.'s Operating Income Loss has declined by 546.5%.
- Historical annual values: Fiscal year 2025: -$25.10 million | Fiscal year 2024: -$26.64 million | Fiscal year 2023: -$29.63 million | Fiscal year 2022: -$30.64 million | Fiscal year 2021: -$22.97 million | Fiscal year 2020: -$19.74 million | Fiscal year 2019: -$17.52 million | Fiscal year 2018: -$15.03 million | Fiscal year 2017: -$8.65 million | Fiscal year 2016: -$3.88 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: